Drug Shortage Report for LORAZEPAM INJECTION USP
| Report ID | 127901 |
| Drug Identification Number | 02388669 |
| Brand name | LORAZEPAM INJECTION USP |
| Common or Proper name | Lorazepam Injection USP |
| Company Name | PFIZER CANADA ULC |
| Market Status | MARKETED |
| Active Ingredient(s) | LORAZEPAM |
| Strength(s) | 4MG |
| Dosage form(s) | SOLUTION |
| Route of administration | INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR INTRAVENOUS |
| Packaging size | 10 x 1mL vial |
| ATC code | N05BA |
| ATC description | ANXIOLYTICS |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | |
| Actual start date | 2020-12-18 |
| Estimated end date | 2021-06-30 |
| Actual end date | |
| Shortage status | Actual shortage |
| Updated date | 2021-03-02 |
| Company comments | Inventory is on preventative allocation. |
| Health Canada comments | |
| Contact Address | 17300 TRANS-CANADA HIGHWAY KIRKLAND, QUEBEC CANADA H9J 2M5 |
| Company contact information | Customer Service / service à la clientèle : 1-888-999-8750 Email / courriel: PharmaCustomerServiceDept@pfizer.com |
Version History
Click on "Compare" below to view the full report history and compare to other versions.